Jørgen Ingerslev

5.4k total citations · 1 hit paper
94 papers, 3.4k citations indexed

About

Jørgen Ingerslev is a scholar working on Hematology, Surgery and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Jørgen Ingerslev has authored 94 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 14 papers in Surgery and 12 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Jørgen Ingerslev's work include Hemophilia Treatment and Research (47 papers), Platelet Disorders and Treatments (32 papers) and Blood Coagulation and Thrombosis Mechanisms (20 papers). Jørgen Ingerslev is often cited by papers focused on Hemophilia Treatment and Research (47 papers), Platelet Disorders and Treatments (32 papers) and Blood Coagulation and Thrombosis Mechanisms (20 papers). Jørgen Ingerslev collaborates with scholars based in Denmark, United States and United Kingdom. Jørgen Ingerslev's co-authors include Benny Sørensen, Gilbert White, Chantal Rothschild, Frits R. Rosendaal, Louis M. Aledort, Jeanne M. Lusher, Christian Fenger‐Eriksen, U. Martinowitz, Aharon Lubetsky and Gili Kenet and has published in prestigious journals such as The Lancet, Blood and FEBS Letters.

In The Last Decade

Jørgen Ingerslev

92 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definitions in Hemophilia

2001 601 citations Jørgen Ingerslev et al. Thrombosis and Haemostasis profile →

Peers

Countries citing papers authored by Jørgen Ingerslev

Since Specialization

Citations

This map shows the geographic impact of Jørgen Ingerslev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jørgen Ingerslev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jørgen Ingerslev more than expected).

Fields of papers citing papers by Jørgen Ingerslev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jørgen Ingerslev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jørgen Ingerslev. The network helps show where Jørgen Ingerslev may publish in the future.

Co-authorship network of co-authors of Jørgen Ingerslev

This figure shows the co-authorship network connecting the top 25 collaborators of Jørgen Ingerslev. A scholar is included among the top collaborators of Jørgen Ingerslev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jørgen Ingerslev. Jørgen Ingerslev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products 2017 ·Thrombosis Research ·Mariann Tang, Christian Fenger‐Eriksen, Per Wierup, Jacob Greisen, Jørgen Ingerslev, Vibeke E. Hjortdal, Benny Sørensen	12
2	Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort 2013 ·Thrombosis and Haemostasis ·Adel Abuzenadah, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ulrich Budde, Türkiz Gursel, Jørgen Ingerslev, I. R. Peake, Anne Goodeve, Daniel J. Hampshire	7
3	Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients 2012 ·Thrombosis and Haemostasis ·U. Martinowitz, Jerzy Windyga, Giovanni Di Minno, (unknown), Ingrid Pabinger, Monika Maas Enriquez, Lawrence Schwartz, Jørgen Ingerslev, (unknown), (unknown)	24
4	Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation – the surgical STER 2010 ·British Journal of Haematology ·Guglielmo Mariani, Alberto Dolce, Angelika Bátorová, Günter Auerswald, Jean‐François Schved, Sergio Siragusa, Mariasanta Napolitano, Jens Knudsen, Jørgen Ingerslev, (unknown)	49
5	Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders 2010 ·Transfusion ·Christian Fenger‐Eriksen, Gary Moore, Savita Rangarajan, Jørgen Ingerslev, Benny Sørensen	93
6	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A 2010 ·BMC Research Notes ·Peter W. Collins, F. Baudo, Angela Huth‐Kühne, Jørgen Ingerslev, Craig M. Kessler, María Eva Mingot‐Castellano, Midori Shima, Jean St‐Louis, H. Lévesque	127
7	Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial 2008 ·Blood Coagulation & Fibrinolysis ·Guy Young, Liselotte S. Ebbesen, Dorthe Viuff, Jorge Di Paola, Barbara A. Konkle, Claude Négrier, John Pasi, Jørgen Ingerslev	52
8	Thrombophilia risk factors are associated with intrauterine foetal death and pregnancy‐related venous thromboembolism 2008 ·Scandinavian Journal of Clinical and Laboratory Investigation ·(unknown), Jørgen Ingerslev, Jannie Dalby Salvig	7
9	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting 2007 ·Thrombosis and Haemostasis ·Elena Santagostino, A. Faradji, Alfonso Iorio, Jan van der Meer, Jørgen Ingerslev, Thierry Lambert, (unknown), Eduard Gorina, R Musso, (unknown)	35
10	Endothelial perturbation: a link between non-dipping and retinopathy in type 2 diabetes? 2007 ·Journal of the American Society of Hypertension ·Søren Tang Knudsen, Peter Jeppesen, Christian Alcaraz Frederiksen, N.H. Andersen, Toke Bek, Jørgen Ingerslev, Carl Erik Mogensen, Per Løgstrup Poulsen	6
11	Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training 2006 ·Metabolism ·Torben Østergård, B. Nyholm, Troels Krarup Hansen, Lars Melholt Rasmussen, Jørgen Ingerslev, Keld E. Sørensen, Hans Erik Bøtker, Bengt Saltin, Ole Schmitz	27
12	Folate Deficiency-Induced Hyperhomocysteinemia Attenuates, and Folic Acid Supplementation Restores, the Functional Activities of Rat Coagulation Factors XII, X, and II 2005 ·Journal of Nutrition ·Liselotte S. Ebbesen, Jørgen Ingerslev	4
13	Recurrent thromboembolism in ovarian cancer 2004 ·Acta Obstetricia Et Gynecologica Scandinavica ·Jens Fuglsang, Jørgen Ingerslev, Hanne Havsteen	2
14	Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis 2003 ·Blood Coagulation & Fibrinolysis ·Benny Sørensen, Peter Johansen, (unknown), Jens Christian Hedemann Sørensen, Jørgen Ingerslev	150
15	Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system 2001 ·British Journal of Haematology ·Birgitte Klug Albertsen, Henrik Daa Schrøder, Jørgen Ingerslev, Preben Jakobsen, Vassilios I. Avramis, Hans‐Joachim Müller, (unknown), Kjeld Schmiegelow	51
16	Efficacy and Safety of Recombinant Factor VIIa in the Prophylaxis of Bleeding in Various Surgical Procedures in Hemophilic Patients with Factor VIII and Factor IX Inhibitors 2000 ·Seminars in Thrombosis and Hemostasis ·Jørgen Ingerslev	81
17	Detection of a novel deletion in the cystathionine β‐synthase (CBS) gene using an improved genomic DNA based method¹ 1998 ·FEBS Letters ·Mette Gaustadnes, Leo A. J. Kluijtmans, Ole Kudsk Jensen, Karsten Boye Rasmussen, Sandra G. Heil, Jan P. Kraus, Henk J. Blom, Jørgen Ingerslev, N. Rüdiger	12
18	Clinical Use of Recombinant FVIIa (rFVIIa) 1998 ·Transfusion Science ·Ulla Hedner, Jørgen Ingerslev	97
19	Diabetes-like alterations in hemostatic parameters after growth hormone administration for one week in normal man 1989 ·Journal of Diabetic Complications ·Jørgen Ingerslev, Per Dahl Christensen, (unknown), Niels Møller, Hans Ørskov, Jens Sandahl Christiansen	7
20	Characteristics of the von willebrand factor in virus in activated F VIII concentrates: The impact of heat treatment 1987 ·Thrombosis Research ·Jørgen Ingerslev, Anne Bukh, K. Wallevik, (unknown), S. Stenbjerg	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact